Search results
Results from the WOW.Com Content Network
Remogliflozin etabonate (INN/USAN) [2] is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes.Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with ...
A single 15 mg dose of mirtazapine to healthy volunteers has been found to result in over 80% occupancy of the H 1 receptor and to induce intense sleepiness. [92] After a short period of chronic treatment, however, the H 1 receptor tends to sensitize and the antihistamine effects become more tolerable. Many patients may also dose at night to ...
The citrate is the least expensive soluble (high bioavailability) oral magnesium salt available in supplements, with 100 mg and 200 mg magnesium typically contained per capsule, tablet or 50 mg/mL in solution. [26]
The structures of solid magnesium citrates have been characterized by X-ray crystallography.In the 1:1 salt, only one carboxylate of citrate is deprotonated. It has the formula Mg(H 2 C 6 H 5 O 7) 2 The other form of magnesium citrate has the formula Mg(HC 6 H 5 O 7)(H 2 O) 2, consisting of the citrate dianion (both carboxylic acids are deprotonated). [1]
The chemical formula for this compound is Mg(C4H6NO4)2. [7] The structure of magnesium aspartate consists of a central magnesium ion that is chelated, or bound, by two aspartate anions. The aspartate moiety contains a carboxyl group (-COOH), an amino group (-NH2), and a second carboxyl group, forming a dicarboxylic amino acid structure. [1] [7]
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). [ 2 ] [ 7 ] [ 6 ] [ 18 ] [ 1 ] [ 19 ] [ 20 ] It is taken for a few days to a few weeks, but no longer than 12 weeks.